BIOCHEMICAL SOCIETY TRANSACTIONS prepared from cholesterol-fed control animals induced greater cholesterol uptake than did the equivalent fractions from normolipidaemic rats in proportion to the increased cholesterol content of the fractions. Lipoproteins isolated from rats receiving the stock diet plus BRL 14280 supported less uptake than did control samples and this can also be explained by their differing cholesterol concentration. However, although supplementation of the cholesterol-containing diet with BRL 14280 did not lower the cholesterol content of chylomicrons or very-low-density lipoproteins there were marked decreases in cholesterol uptake by the aortic rings and we attribute this response to the presence of the substituted triacylglycerol.
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Cholesterol turnover was also measured in uivo in groups of eight rats 24 h after an intraperitoneal dose of uCi/lOOg body wt.) . Adding BRL 14280 to the stock diet decreased lipoprotein cholesterol uptake into the aorta (-40%) and kidneys (-20%) and dietary cholesterol promoted uptake into aorta (+85%) and kidneys (+90%) in support of the results in vitro, but addition of BRL 14280 to the cholesterolsupplemented diet did not influence cholesterol turnover in uiuo.
This lack of effect is explained by the rapid hepatic clearance of remnant particles after triacylglycerol hydrolysis by adipose tissue lipoprotein lipase. Thus although the hepatic and intestinal production of a substituted glycerolipid may be a useful mechanism for the efficient delivery of an agent to adipose tissue, the potential as a novel approach to the treatment of disorders in lipid metabolism and atherosclerosis remains to be established. It was the purpose of the present experiments to examine in more detail the relationship between lipid-lowering activity and CoA esterification when the latter was reflected in the subsequent formation of a substituted triacylglycerol. By using methods previously described (Fears et al., 1978) we investigated various compounds, described in the literature as hypolipidaemic agents or discovered by us to be so, for their ability to form a substituted glycerolipid from [ l-14Clglycerol in vitro. When compared with the control incorporation of approx. l00nmol of glycerol/h per g of liver into phospholipid and triacylglycerol and 25nmol of glycerol/h per g of liver into diacylglycerol, substantial quantities of novel glycerolipids were produced by the following compounds at a concentration of 0.5 mM (results are expressed as nmol of glycerol incorporated/h per g of liver, being the mean of two experiments; each analysis was performed in triplicate): BRL I46 1 1 [ethyl (pchlorophenoxymethyloxy)benzoatel, 45 nmol; BRL 16700 (ethyl 3-(4-~rotyloxyphenyl)propionate 1, 40 nmol; cetaben I phexadecylaminobenzoic acid], 65 nmol; RMI 145 14 (5-tetradecyloxy-2-furoic acid), 20 nmol. 'Benzmalacene and phenylbutyric acid were inactive. The results for cetaben and RMI 14514 are consistent with the claims for an effect on CoA metabolism (Largia et al., 1976; Kariya & Wille, 1978) . When cetaben, BRL 14611 or BRL 16700 were included as a supplement to the stock diet (Oxoid breeding diet) fed to groups of eight rats for 7 days the characteristic metabolites accumulated in adipose tissue and the serum concentrations of cholesterol and triacylglycerol were lowered.
In addition to the known hypolipidaemic agents we have also identified several anti-inflammatory compounds, e.g. fenoprofen, ibuprofen, as able to form substituted glycerolipids (Fears et al., 1978), although they were not known to exert other effects on lipid metabolism. We have now obtained some correlation between their capacity to form an abnormal triacylglycerol and inhibition of synthesis of sterols and fatty acid from [I-I4C1acetate in liver slices in vitro as measured by the method of Fears & Morgan (1976). At 0.1 mM, fenoprofen and ibuprofen supported an incorporation of approx. 80nmol of glycerollh per g of liver into the substituted triacylglycerol, a rate equivalent to the synthesis of conventional triacylglycerol. Ketoprofen formed less metabolite (approx. IOnmol/h per g) and flurbiprofen and indomethacin appeared inactive. Fenoprofen inhibited cholesterogenesis from acetate by 86% and fatty acid synthesis by 66%, ibuprofen inhibited by 60% and 53% respectively. Ketoprofen and flurbiprofen did not affect cholesterogenesis and only weakly inhibited fatty acid synthesis, whereas indomethacin was inactive.
To obtain further information, fenoprofen was included as a supplement (0.1%) to the stock diet fed to a group of six rats for 7 days. In comparison with the control group, serum cholesterol was lowered from 68 k 2.1 to 56 5 4.3 mg/100ml ( P < 0.05) and serum triacylglycerol from 140 k 1 1 to 82 f 6.4 mg/100ml ( P < 0.0 1). Hepatic cholesterogenesis, measured in uivo 1 h after an intraperitoneal injection of 3H,0 (1.5mCi/100g body wt.) in 0.9% NaCl (0.1m1/100g body wt.), was decreased by fenoprofen from 400 k 40 to 230 f 30,uglh per liver ( P < 0.01).
The results described in the present communication support the suggestion that lipid-lowering activity for a variety of carboxylic acids can be explained by depletion of CoA pools due to the production of novel CoA esters, which subsequently form glycerolipid metabolites. However, this esterification of an exogenous compound will not necessarily lead to hypolipidaemia if circulating lipid concentrations are maintained from the diet rather than by endogenous synthesis. Thus we have observed that BRL 14280 and BRL 16700 are not hypolipidaemic when included in diets supplemented with cholesterol (1%) or containing a high proportion of fat (40% of 596th MEETING. LANCASTER energy intake) even though the substituted glycerolipids circulate on chylomicrons and very-low-density lipoproteins and accumulate in liver and adipose tissue. The metabolic effects of administering specific inhibitors of long-chain-fatty-acid oxidation are of considerable practical and theoretical importance (see Sherratt, I98 1). Tutwiler et al.
(1 978) introduced methyl 2-tetradecyloxiran-2-carboxylate, which is hypoglycaemic in starved, but not fed, animals, and is thought to be a specific inhibitor of long-chain-fatty-acid oxidation at the stage of carnitine palmitoyltransferase I located on the outer face of the mitochondria1 inner membrane (Tutwiler & Dellevigne, 1978) . We report some chronic metabolic effects of ethyl 2-[5-(4-chlorophenyl)pentyl1oxiran-2-carboxylate, a hypoglycaemic analogue of methyl 2-tetradecyloxiran-2-carboxylate (kindly supplied by Dr. Gerhard Ludwig, the Byk Gulden Lomberg Chemische Fabrik G.m.b.H., Konstanz, Germany).
Three groups of 20 male albino Wistar rats were fed on a standard diet (containing about 3% fat) with 0, 0.1% or 0.2% ethyl 2-[5-(4-chorophenyl)pentyl1oxiran-2-carboxylate for 12 weeks. The concentrations of blood, pyruvate, lactate, alanine, acetoacetate, 3-hydroxybutyrate, glycerol, total triacylglycerols, cholesterol and unesterified fatty acids were determined by standard enzymic methods at the start of the experiment and after 6 and 12 weeks. Livers and skeletal muscles of six rats from each group were freeze-clamped after 12 weeks and analysed for glycogen, glucose, glycolytic intermediates, pyruvate, lactate, acetoacetate, 3-hydroxybutyrate, some amino acids, some tricarboxylic acidcycle intermediates, CoA and carnitine and their esters, adenine nucleotides and triacylglycerols. There was no significant difference in weight gain in either treated group compared with the controls for up to 6 weeks, but by 12 weeks the high-dose group was gaining weight more slowly (13% less weight, Pi: 0.0025). There were no significant differences in liver weights expressed as percentages of total body weight. Pale 'fatty' livers occurred in some of the rats in the high-dose group. Plasma total triacylglycerol and cholesterol concentrations were decreased in both treated groups after 6 weeks and 12 weeks, by 30-50 and 40% respectively and plasma unesterified fatty acid concentrations were decreased by 50% in the low-dose group after 12 weeks. Very-low-density lipoprotein concentrations decreased in treated animals, whereas those of high-density lipoproteins changed very little. Other significant changes in the concentrations of blood metabolites were a 25% lowering of alanine in both groups, and lowering of both glucose and lactate by about 30% in the high-dose group.
The significant changes in metabolite concentrations found in livers of treated rats are given in Table 1 . The most marked were 2-3-fold increases in the concentrations of CoA, acetyl-CoA, carnitine and acetylcarnitine. Decreased concentrations of glucose 6-phosphate were consistent with an impaired rate of gluconeogenesis, although concentrations of acetyl-CoA appeared adequate to maintain pyruvate carboxylase activity. Decreases in glycogen concentrations were not significant but there was an inverse relationship between the glycogen and fat contents in individual livers. There were few significant changes in metabolite concentrations in skeletal muscle of treated animals, although, as in liver, glycerol 3-phosphate was increased ( Table 1) 
